The Research Animal Support Facility (RASF) has been a shared resource since the original Cancer Center Support Grant (CCSG) was awarded in 1975. The University of Texas M.D. Anderson Cancer Center has supported the RASF over these years, using institutional funds for the acquisition of major operational equipment and for remodeling and utility upgrades. The RASF has two distinct sites. One is within the perimeter of the Texas Medical Center, and the other is approximately 1 mile south of the Texas Medical Center at the Smith Research Building. Both animal facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Core International, have an approved Animal Welfare Assurance Form (A3343-01), and are part of a research facility registered with the United States Department of Agriculture (74-R-065). The RASF is composed of three specific-pathogen-free (SPF) general rodent barriers, an SPF transgenic mouse barrier, a biohazard-use facility, conventional rodent housing, large-animal housing (for monkeys, dogs, pigs, and rabbits) and quarantine facilities. The RASF maintains approximately 37,000 animals daily; 98% are rodents, most of which are mice. The remaining 2% are monkeys, dogs, pigs, rabbits, guinea pigs, hamsters, and frogs. Also used are sea urchins and fruit flies. Animals are used to answer questions about how to diagnose, treat, and prevent cancer and to understand its causes. Investigators in all 13 research departments and in 24 of 29 clinical departments are supported by the RASF. In addition, clinical, surgical, diagnostic imaging,, and irradiation facilities and services are provided, as are diagnostic and pathology laboratory facilities and services. Specific SPF facilities for severe combined immuno-deficiency (SCID) mice use are also provided, and new, expanded SPF facilities for knockout and transgenic mice production and use are being developed, with occupancy expected in about April, 1998.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-25
Application #
6334914
Study Section
Project Start
2000-07-18
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
25
Fiscal Year
2000
Total Cost
$332,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141

Showing the most recent 10 out of 12418 publications